FDA approves revolutionary treatment for sickle cell disease
Food and Drug Administration approved two revolutionary cell-based gene therapies for treating sickle cell disease in patients 12 and older, Casgevy and Lyfgenia, the first of their kind, on Friday.
According to the American Society of Hematology, the approval of Vertex and Bluebird's therapy treatment made history as a new class of drugs toward a cure for the disease.
Dr. Daniel Ram, assistant professor of medicine at UCF in the Burnett School of Biomedical Sciences, said these treatments gen
According to the American Society of Hematology, the approval of Vertex and Bluebird's therapy treatment made history as a new class of drugs toward a cure for the disease.
Dr. Daniel Ram, assistant professor of medicine at UCF in the Burnett School of Biomedical Sciences, said these treatments gen